Nayla Mumneh, MD, Allergy & Immunology, East Hanover, NJ

NaylaMumnehMDFAAAAI, FACAAI

Allergy & Immunology East Hanover, NJ

Medical director respiratory at Novartis

Dr. Mumneh is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mumneh's full profile

Already have an account?

Summary

  • Dr. Nayla Mumneh was born and raised in Beirut, Lebanon. She earned her medical degree at the American University of Beirut. In 1997, Dr. Mumneh completed her training in internal medicine at Carney Hospital in Boston, Massachusetts. She went on to specialize in allergy and immunology at New York Presbyterian Hospital/Cornell University Medical Center in New York, New York. She is board certified in Allergy and Immunology.

    From 1999 until 2019, she was in private practice in New Jersey. During this time, she gained extensive experience in the treatment of allergic and immunologic disorders, asthma and skin disorders. She served as principal investigator of multiple clinical trials, sponsored by pharmaceutical companies, at her sites. She also participated in several industry-sponsored advisory board meetings. Dr. Mumneh has authored case study articles on hereditary angioedema.

    As Clinical Assistant Professor of Medicine at Rutgers-New Jersey Medical School between 2013 and 2016, Dr. Mumneh supervised the clinical training of allergy and immunology fellows and medical students.
    Dr. Mumneh was president of the New Jersey Allergy Asthma and Immunology Society in 2012 and was on its board of directors from 2009 until 2015. She has been active in community outreach programs to increase asthma awareness and participated in asthma screenings sponsored by the AAAAI and the Woodbridge Township Mayor’s annual health fair.

    Dr. Mumneh has received several awards throughout her career, including being recognized yearly as a Castle and Connolly Top doctor and NJ Top Doctor since 2014. She is a Fellow of both AAAAI and ACAAI and a member of the New York, New Jersey and Pennsylvania allergy societies.

    She is currently a medical director in the respiratory division at Novartis.

Education & Training

  • New York Presbyterian Hospital
    New York Presbyterian HospitalFellowship, Allergy and Immunology, 1997 - 1999
  • Caritas Carney HospitalResidency, Internal Medicine, 1994 - 1997
  • American University of Beirut Faculty of Medicine
    American University of Beirut Faculty of MedicineClass of 1992

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1999 - 2021
  • American Board of Allergy and Immunology Allergy & Immunology

Awards, Honors, & Recognition

  • Castle And Connolly Top Doctor Castle and Connolly, 2014-2019
  • Top Doctors New York Metro Area 2016 Castle and Connolly, 2016
  • New York Metro Area Top Doctor Castle Connolly, 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Committees

  • Board member, Asthma Advisory Board-Genentech 2016 - Present

Research History

  • Principal InvestigatorPROSPERO-A Prospective Observational Study to Evaluate Predictors of Clinical Response to Omalizumab2013 - Present
  • Principal InvestigatorA Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet in Children With a History of Ragweed-Induced Rhinoconjunctivitis, Merck2015 - 2018
  • Principal Investigator-OSMO Trial-GSKGlaxoSmithKline / “A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (the OSMO study)”2016 - 2017
  • Principle Investigator-SAHARA Trial-ShireA Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Administration of 2000 U of C1 Esterase Inhibitor [human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents2016 - 2017
  • Principal InvestigatorUnderstanding Refractory Chronic Idiopathic Urticaria (CIU) in the US, Novartis2015 - 2015
  • Principal InvestigatorPatient Registry for Berinert- A C1 Esterase Inhibitor2012 - 2014
  • Principal InvestigatorA Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity With Exposure to KALBITOR (Ecallantide) for the Treatment of Acute Attacks of HAE2011 - 2013

Professional Memberships

Other Languages

  • Arabic, French, Spanish

Industry Relationships

  • Speaker Bureau, Bausch and LombBepreve2012 - Present